Overview of the drug development pipeline for lipodystrophy syndrome
Lipodystrophy syndrome is a rare genetic disorder, which causes fat loss or abnormal distribution or accumulation of fat tissues in the body. The amount of fat loss can be determined by the severity of metabolic complications. Lipodystrophy syndrome causes several metabolic complications such as insulin resistance, diabetes mellitus, hepatic steatosis, and dyslipidemia. According to the National Institutes of Health (NIH), lipodystrophy is a rare disease. The familial partial lipodystrophy is estimated to be affecting one in a million people. Women are found to be more affected by familial partial lipodystrophy as compared with men. The growing instances of the lipodystrophy syndrome are expected to proliferate the drug development for lipodystrophy syndrome in the next few years.
According to our pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II and pre-clinical stages. For instance, sponsors such as Ambrx developed ARX328 and Bolder BioTechnology developed BBT-031, which are in the pre-clinical stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under discovery, phase III, phase II/III stages, IND, and phase I.
Want a bigger picture? Try a FREE sample of this report now!
Pipeline analysis report on drug development for lipodystrophy syndrome: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of lipodystrophy syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Ambrx
- Amunix
- Idera
Therapeutic assessment of the drug development pipeline for lipodystrophy syndrome by route of administration
- Oral
- Subcutaneous
- Intravenous + subcutaneous
The oral route of administration (ROA) involves the administration of the drug through the mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration. The drug is administered through the mouth cavity.
Therapeutic assessment of the drug development pipeline for lipodystrophy syndrome by therapeutic modality
- Biological
- Oligonucleotides
- Small molecule
- Recombinant protein
According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for lipodystrophy syndrome are being developed as oligonucleotides. Oligonucleotides are polynucleotides whose molecules contain a relatively small number of nucleotides. They are synthesized to be used as a therapeutic agent by blocking the disease process through altering the synthesis of a particular protein.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for lipodystrophy syndrome?
- What are the companies that are currently involved in the development of drug development molecules for lipodystrophy syndrome?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.